SEC Form 4 · accession 0001231589-26-000013
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul A Mahon
Officer — EVP & GENERAL COUNSEL
Period of report
Jun 4, 2026
Accepted (ET)
Jun 4, 2026 · 5:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 4, 2026 | M | 8,300 | $146.03 | A | 53,472 | D | |
| Common Stock | Jun 4, 2026 | S | 200 | $539.76 | D | 53,272 | D | |
| Common StockF2 | Jun 4, 2026 | S | 840 | $543.8893 | D | 52,432 | D | |
| Common StockF3 | Jun 4, 2026 | S | 374 | $545.2671 | D | 52,058 | D | |
| Common StockF4 | Jun 4, 2026 | S | 2,627 | $546.4178 | D | 49,431 | D | |
| Common StockF5 | Jun 4, 2026 | S | 935 | $547.1108 | D | 48,496 | D | |
| Common StockF6 | Jun 4, 2026 | S | 1,481 | $548.425 | D | 47,015 | D | |
| Common StockF7 | Jun 4, 2026 | S | 593 | $549.4948 | D | 46,422 | D | |
| Common Stock | Jun 4, 2026 | S | 1,250 | $549.47 | D | 45,172 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $146.03 | Jun 4, 2026 | M | 8,300 | D | Mar 15, 2020 | Mar 15, 2027 | Common Stock | 8,300 | 105,640 | D |
Explanation of responses
- F1This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $543.59 to $544.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $544.795 to $545.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $545.80 to $546.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $546.80 to $547.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $547.90 to $548.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $549.12 to $549.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.